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fd. Note - This overview was originally presented at the 
International Symposium on Clinical Disorders of Bone 
and Mineral Metabolism, May 9-13,1983. The following 
list indicates the presentations given in this session at the 
Symposium and the contents ofthe corresponding chap-
ter in the Proceedings of the Symposium published by 
Excerpta Medica. The numbers in parentheses refer to 
pages in this volume. Complete information about the 
contents of the Proceedings can be found at the back of 
this issue. 
Tracer measurements of bone remodel ing and their sig-
nificance in involutional osteoporosis. J. Reeve, M. 
Arlot, R. Hesp, M. Tellez, and P.J. Meunier (99) 
Excretion of urinary hydroxyprol ine peptides in the 
assessment of bone collagen deposition and resorption. 
K.I. Kivirikko (105) 
Procollagen extension peptides as markers of collagen 
synthesis. L.S. Simon and S.M. Krane (108) 
Essential to understandingthe pathophysiology of skele-
tal diseases and evaluating the results of therapy are 
markers for bone cell function and a means to accurately 
measure the synthesis and degradation o f the extracellu-
lar matrix of bone. As knowledge has advanced concern-
ing the structure and composit ion of bone and pathways 
of biosynthesis o f the skeletal components, new markers 
have become available. The util ity of techniques that 
have been used for years to quantitate bone formation 
and resorption now have a different perspective. 
Bone is a two phase material composed of an inorganic 
mineral phase (~65% of weight) and an organic matrix 
(—35% of weight). The calcium-phosphorus mineral 
phase, at least part of which is organized with respect to 
the collagenous port ion o f the organic matrix, consists of 
poorly crystalline hydroxyapatite (1). The composition of 
the organic matrix of bone is described in Table I. 
The collagen of bone is almost exclusively type I, identical 
in primary structure to the type I collagen in other organs 
(2). However, there are differences in certain posttransla-
tional modifications between the type I collagens in skin 
and bone, particularly with respect to content of hydroxy-
lysine, hydroxylysine glycosides, and the hydroxylysine-
derived hydroxypyridinium crosslinks (3). The distinctive 
collagenous product of the osteoblast can thus be ascribed 
to the expression of genes coding for proteins other than 
the component o:1(l) and cr2(l) chains. 
Over the past several years, several noncollagenous pro-
teins unique to bone have been identified and character-
ized. The isolation of the a-carboxyglutamic acid (Gla) 
protein (osteocalcin), osteonectin, and bone proteogly-
can has been made possible by avoiding artifacts intro-
duced by mechanical shearing forces that cause release 
of proteases during demineralization and extraction. 
Osteonectin is a good example (4,5). It represents more 
TABLE I 
Composit ion of the Organic Matrix of Bone 
I. Type I col lagen: 90-95% of total 
I I . Noncollagenous proteins 
A. ' 'T rue" matrix constituents (osteoblast-derived) 
1. Osteonectin 
2. Bone sialoprotein 
3. Bone proteoglycan 
4. Other glycoproteins 
5. Phosphoproteins 
B. Bound to mineral phase (osteoblast-derived) 
1. Bone Gla protein (osteocalcin) 
C. Serum-derived 
1. cr^-HS glycoprotein 
2. Other serum proteins 
•Department of Medicine, Harvard Medical School and Massachusetts General 
Hospital, Boston 
Address reprint requests to Dr. Krane, Massachusetts Ceneral Hospital, 32 Fruit 
Street, Boston, MA 02114. 
201 
Krane 
than 25% of t h e n o n c o l l a g e n o u s p ro te ins of b o v i n e 
bone. Osteonection, which is made by osteoblasts, may 
have a functional as well as structural role in regulating 
collagen and protein synthesis. Radioimmunoassays de-
veloped for this protein should serve as another marker 
for matrix protein metabolism in humans. 
In the process of bone format ion, mineral ions enter the 
inorganic phase and are removed in the process of bone 
resorption. Thus, the kinetics of rad local cium and radio-
strontrium uptake by the skeleton provide a means to 
quantitate bone formation and resorption. Validation of 
the derived rates is best accomplished by employing an 
independent method. In this Symposium, Reeve and 
associates (pp. 99 ff.) have described histomorphometric 
methods with double tetracycline labeling to calculate 
local bone formation rates. These correlate with whole 
body radiotracer data that are properly corrected for 
long-term exchange processes. 
As suggested in Fig. 1, the synthetic activities of osteo-
blasts might be monitored without direct bone sampling 
if byproducts of the matrix components that become 
part of bone were released quantitatively and easily 
measured. Moreover, the release of degradation pro-
ducts of bone resorption could provide an accurate 
index of these processes. Considerable effort has been 
devoted to the measurements of collagen-related markers. 
Many investigators have relied on measurement of ur i-
nary hydroxyproline excretion to evaluate metabolic 
bone diseases. Unfortunately, total urinary hydroxypro-
line represents only 10-20% of that released from colla-
gen degradation, since free hydroxyprol ine released 
from collagen-derived oligopeptides is oxidized to a 
number of other products. In individuals who excrete 
relatively low amounts of urinary hydroxyproline, e.g., 
osteoporotics, a minor change in catabolism resulting 
from therapy could produce major changes in hydroxy-
proline excretion. Furthermore, significant amounts of 
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Fig.1 
Schematic Representation of Bone Formation and Resorption. 
urinary hydroxypro l ine are der ived f rom col lagen 
sequences other than bone, particularly in those indi-
viduals excreting less than 40 mg/day. For these reasons, 
other measurements have been used. Measurement of 
hydroxylysine and its glycosides more accurately reflects 
the amount and source of collagen degradation. Although 
these methods are tedious, they are constantly being 
modif ied. Kivirikko's review (pp. 105 ff.) discussed the 
measurement of serum levels of posttranslat ional 
collagen-modifying enzymes in disease states. 
Collagens are synthesized as procollagens, which are 
molecules with extra sequences at either end that must 
be cleaved when the mature fibri l is formed extracellu-
larly. Simon and I (pp. 108 ff.) discussed the use of 
radioimmunoassays for two of the procollagen exten-
sions to evaluate changes in Paget's disease and other 
conditions. The procollagen extensions are examples of 
byproducts of synthesis (Fig.1). The aminoterminal pep-
tides may have a regulatory role in the feedback control 
of collagen formation. 
A radioimmunoassay of bone Gla protein has recently 
been developed to detect markers for the noncollagen-
ous proteins of bone. This 49-amino acid polypeptide is 
produced by osteoblasts, and its rate of synthesis is sub-
ject to endocrine control. Probably synthesized at some 
stage in bone formation later than that of noncollagen-
ous proteins such as osteonectin, its role in bone remains 
to bedef ined. Nevertheless, this Gla protein is un iqueto 
bone and circulates in normal human plasma. Moreover, 
as discussed by Deftos and Catherwood (pp. 112 ff.) 
circulating levels change in bone diseases and in response 
to alterations in parathyroid hormone secretion. Whether 
levels of bone Gla protein reflect bone formation pr i -
marily or resorption remains to be determined. 
Several noncollagenous proteins of bone that are not 
produced by bone cells, such as albumin and Oj-yiS 
glycoprotein, become part of the extracellular matrix in 
the course of bone formation. The a2-HS glycoprotein is 
synthesized in the liver, released into the circulation, 
and selectively taken up by bone. Thus, levels of this 
protein in plasma might reflect inversely the rate of bone 
format ion. Smith, et al (pp. 116 ff.) discussed their results 
using a radioimmunoassay for aj-HS glycoprotein in 
patients with metabolic bone diseases. The direction of 
change in levels of the protein was as predicted, but the 
change was not great enough for the measurement to be 
widely adopted. 
To quantitate bone format ion, it would be highly desira-
ble to have a measurement that reflects osteoblastic 
activity directly. Measurements of circulating alkaline 
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phosphatase activity have been available for over 50 
years. Bone is rich in this enzyme, which is localized 
predominantly in osteoblasts. Despite this evidence, the 
role of alkaline phosphatase in bone formation has yet to 
be def ined. As discussed by Whyte (pp. 120 ff .), the 
enzyme in bone can be distinguished f rom that in other 
tissues by immunological and kinetic methods. 
Considerable progress has been made to develop markers 
for bone formation and resorption that do not depend 
on bone biopsy. In the future, many methods for meas-
uring these markers, which are currently being devel-
oped, should provide accurate, quantitative information 
for diagnosis, understanding the pathophysiology of 
metabolic bone diseases, and evaluation of therapy. 
References 
1. Gl imcher MJ, Bonar LC, Crynpas M D , Landis WJ, Roufosse AH. J 
Crystal Growth 1981;53:100. 
2. Krane SM, Simon LS. In: Veis A, ed. The chemistry and biology of 
mineral ized connective tissues. North Hol land: Elsevier, 1981:185. 
3. Eyre DR. In: Veis, A ed. The chemistry and biology of mineral ized 
connective tissues. North Hol land: Elsevier, 1981:51. 
4. Termine JD, Belcourt AB, Conn K M , Kleinman HK. J Biol Chem 
1981:256:10403. 
5. TermineJD, Kleinman HK, Whitson SW, Conn KM,McGarvey ML, 
Mart in GR. Cell 1981;26:99. 
203 
